Dutriaux C, Robert C, Grob JJ, Mortier L, et al. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases. Eur J Cancer 2022;175:254-262.
PMID: 36170791